{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028184","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.574778+00:00","generated_at":"2026-06-22T07:53:09.037162+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corcept Q3 revenue $101.7M (+5.8% YoY); tightens 2022 guidance to $400-410M","bullets":["Diluted EPS $0.30 vs $0.24 in Q3 2021; net income $34.6M.","Tightened FY 2022 revenue guidance to $400-410M from prior range.","Cash and investments $401.2M at Sept 30, up from $382M at June 30.","Operating expenses $69.8M (+16.5% YoY) on clinical and commercial expansion.","Enrolling pivotal Phase 3 ROSELLA trial in ovarian cancer; GRATITUDE AIWG data expected Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028184","json":"https://secwatch.observer/filing/0001628280-22-028184.json","markdown":"https://secwatch.observer/filing/0001628280-22-028184.md","text":"https://secwatch.observer/filing/0001628280-22-028184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828022028184/0001628280-22-028184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828022028184/cort-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:53:09.037162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"adc0e04cc2617a69fec4de493e8ad7efeda22b13","claim":"CORCEPT THERAPEUTICS INC reported the quarter ended September 30, 2022 results: revenue $101.7 million, net income $34.6 million, EPS $0.30. Guidance reaffirmed.","evidence_excerpt":"Revenue of $101.7 million, compared to $96.1 million in third quarter 2021 • Tightened 2022 revenue guidance of $400 – $410 million • Diluted net income per common share of $0.30, compared to $0.24 in third quarter 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1088856/000162828022028184/0001628280-22-028184-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$101.7 million"},{"label":"Net income","value":"$34.6 million"},{"label":"EPS","value":"$0.30"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}